Jeffrey Yachnin

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Sten Nilsson, Lars Franzén, Christopher Parker et al. · The Lancet Oncology · 2007 · 491 citations

Bone-targeted Radium-223, Urology, Genitourinary Cancer +6

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Sören Lehmann, Vladimir J.N. Bykov, Dina Ali et al. · Journal of Clinical Oncology · 2012 · 397 citations · Full text

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong et al. · The Lancet Oncology · 2019 · 217 citations · Full text

Innovatv 201, Tisotumab Vedotin, Medicine +10

<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer et al. · Clinical Cancer Research · 2018 · 161 citations · Full text

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Heikki Joensuu, Judith Fraser, Hans Wildiers et al. · JAMA Oncology · 2018 · 145 citations · Full text